Natazia generics — when can they launch?
Natazia (DIENOGEST) · Mochida Pharmaceutical Co., Ltd. · 1 active US patent · 1 expired
Where Natazia sits in the generic timeline
Imminent generic cliff: earliest active US patent for Natazia expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 1 patent
FDA U-codes carved out by Natazia patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1240 | (no description) |
Sample patent estate
Showing 1 of 1 active US patents. View full estate on the Natazia drug page →
-
This patent protects a combination oral contraceptive and treatment for dysfunctional uterine bleeding containing estradiol valerate and dienogest.USPTO title: Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
Sources
- FDA Orange Book — patents listed against Natazia (NDA filed 2010)
- Natazia drug profile — full patent estate, indications, clinical trials, pricing
- Mochida Pharmaceutical Co., Ltd. patent portfolio
- Patent cliff 2028 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Natazia — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →